Key terms

About EOLS

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest EOLS news

Today 1:57am ET Evolus’s Strong Q1 Performance and Solid Growth Trajectory Justify Buy Rating by TipRanks Today 1:17am ET Evolus Outperforms Expectations with Strong Q1 Sales and Promising Growth Trajectory by TipRanks May 06 4:36am ET Barclays Releases a Buy Rating on Evolus (EOLS) by TipRanks Apr 17 4:06pm ET Evolus discloses publication of Phase 2 study data of 40U Jeuveau by TipRanks Apr 03 4:43pm ET Evolus Inc Announces Strategic Board Renewal Plans by TipRanks Mar 21 7:34am ET 5 Stocks Hedge Funds Love and have Analysts Support by TipRanks Mar 21 1:59am ET Evolus (NASDAQ:EOLS): An Attractive Aesthetics Stock for Growth Investors by TipRanks Mar 14 5:00am ET Analysts Offer Insights on Healthcare Companies: Sangamo Biosciences (SGMO) and Evolus (EOLS) by TipRanks Mar 11 7:25am ET Evolus 3.55M share Spot Secondary priced at $14.07 by TipRanks Mar 11 2:35am ET Evolus (EOLS) Receives a Buy from Barclays by TipRanks Mar 11 2:32am ET 3 Best Stocks to Buy Now, 3/11/2024, According to Top Analysts by TipRanks Mar 11 12:45am ET Evolus Poised for Growth: Buy Rating Affirmed with $25 Price Target Amid Profitability Forecast and Competitive Market Positioning by TipRanks Mar 08 8:25am ET Evolus price target raised to $25 from $23 at Stifel by TipRanks Mar 08 6:55am ET Evolus Poised for Growth: Surpassing Q4 Expectations and Accelerating Profitability by TipRanks Mar 08 6:41am ET Evolus price target raised to $23 from $20 at Mizuho by TipRanks Mar 08 6:27am ET Evolus: A Promising Trajectory Toward Profitability and Market Expansion by TipRanks Mar 07 4:30pm ET Evolus sees FY24 revenue $255M-$265M, consensus $261.17M by TipRanks Mar 07 4:29pm ET Evolus reports Q4 EPS (21c), consensus (7c) by TipRanks Mar 01 12:40pm ET Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Akero Therapeutics (AKRO) by TipRanks
Aug 08 5:15am ET Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline by NewsFile

EOLS Financials

1-year income & revenue

Key terms

EOLS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

EOLS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Bruce Garelick was found guilty of insider trading
John Minchillo/AP
Investor found guilty in Trump Media insider trading case
People walk toward an entrance to Disneyland in Anaheim, California on April 24, 2023.
Mario Tama/Getty Images/File
Americans are shopping less but they’re still spending on flights, hotels and Disneyland
Scaffolding and construction netting near an apartment building in New York, US, on Wednesday, Oct. 11, 2023. Monthly fees and expenses for inspections, insurance and climate-friendly upgrades are squeezing residents of the city's many co-op and condo buildings. Photographer: Michael Nagle/Bloomberg
Michael Nagle/Bloomberg/Getty Images
For US renters, the chance of owning a home is going from bad to worse
Close-up detail of the Disney+ app icon on an Apple iPhone 12 Pro smartphone screen, on November 11, 2020. (Photo by Phil Barker/Future Publishing via Getty Images)
Phil Barker/Future Publishing/Getty Images
Disney just had its worst day in a year and a half